Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities Webcast (2022)

This course is intended for urologists and advanced practice providers (APPs) interested in optimizing detection, staging and follow-up of genitourinary malignancies through the use of molecular imaging opportunities. The attendee will explore current diagnostic imaging modalities and their performance characteristics, along with imaging guidelines for initial cancer staging. This will lead into an introduction of novel molecular imaging tests and their clinical applications. Emphasis will be placed on novel positron emission tomography (PET) radiopharmaceutical agents in combination with computerized tomography (CT) or magnetic resonance imaging (MRI) for prostate (FDG, choline, acetate, NaF, FACBC, PSMA), kidney (FDG, sestamibi, carbonic anhydrase) and bladder (FDG, choline, acetate) as well as testis cancer (FDG). Differences among the imaging modalities and how they compare to existing diagnostic tests will be highlighted. Discussions will focus on practical case based examples and integration into clinical practice. At the end of this course, participants should be able to independently determine the strengths and limitations of emerging molecular imaging modalities in urologic oncology. This multidisciplinary course led by a combination of urologists, nuclear medicine experts, and medical oncologists will be conducted through a hybrid approach of lectures and attendee participation.


Support provided by independent educational grants from:

Exact Sciences
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney and urothelial cancer detection, staging and follow-up.
  2. Determine the benefits of combined functional and anatomical information gained through accurate matching of anatomical (CT/MRI) and functional (PET) images.
  3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.
  4. Utilize performance characteristics of standard and emerging molecular imaging modalities to stage urologic oncology patients.
  5. Describe the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

 COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Marc Bjurlin, DO

has a financial relationship (Other) with Intuitive Surgical;.

Michael Gorin, MD

has a financial relationship (Scientific Study or Trial (Oncology)) with Deep Bio, Inc.;.
has a financial relationship (Consultant or Advisor (Non-urology Healthcare Related)) with OBP Medical Corporation;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Progenics Pharmaceuticals;.
has a financial relationship (Consultant or Advisor (Oncology)) with Galvanize Therapeutics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Corbin Clinical Resources (Perineologic);.
has a financial relationship (Scientific Study or Trial (Oncology)) with OPKO Health, Inc.;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Lantheus Medical Imaging, Inc.;.
has a financial relationship (Consultant or Advisor (Oncology)) with KOELIS, Inc.;.
has a financial relationship (Consultant or Advisor (General Urology)) with Ambu, Inc.;.
has a financial relationship (Consultant or Advisor (Oncology)) with BK Medical ApS;.
has a financial relationship (Consultant or Advisor (Oncology)) with Blue Earth Diagnostics;.

Tracy Rose, MD

has no relevant financial relationships to disclose at this time.


Learners will participate in this online educational activity by viewing the webcast, completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2022
Expiration Date: May, 2023


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group. 
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning 
  • Selection of alternative faculty for specific topic


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.



 The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.


Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.


The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.


Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.


The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.